Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Avanir Pharmaceuticals, Inc.

http://www.avanir.com

Latest From Avanir Pharmaceuticals, Inc.

Asia Deal Watch: LianBio Partners With Pfizer In Greater China, Gets Financial Backing

Plus deals involving Takeda/OrigiMed, Amcure/Hinova, AUM/Newsoara, Taiho/Lung Therapeutics, 3D Medicines/Aravive, HitGen/Baiyunshan, Dong-A/Jiangsu Hengrui, and Crescita/Juyou.

Deals Business Strategies

Finance Watch: Have Biopharma IPOs Hit Their Limit?

Public Company Edition: Three companies postponed or withdrew their offerings, but drug developers continue to pursue IPOs. Also, Biocon, BMS and Epizyme raised money through new debt, Five Prime capitalized on positive data and Synthetic Biologic engaged a strategic advisor.

Financing Business Strategies

Tech Transfer Roundup: NCI Licenses Leukemia, Brain Cancer Candidates To Vor, Connectyx

NIH’s National Cancer Institute licensed two experimental cancer therapies in the past month to biopharma firms, leading a heavy slate of cancer-focused tech transfer deal-making.

Deals Research and Development Strategies

Bristol Highlights Growth Is Not Coming From Opdivo Alone

Recent launches and products acquired with Celgene are helping BMS grow, CEO Caforio said, while Opdivo is moving toward resuming growth thanks to first-line NSCLC and other factors.

Sales & Earnings Business Strategies
See All

Company Information

  • Other Names / Subsidiaries
    • Alamo Pharmaceuticals, LLC
UsernamePublicRestriction

Register